![]() |
市场调查报告书
商品编码
1822440
2032 年儿科神经系统器材市场预测:按产品、疾病状况、服务/疗法、最终用户和地区分類的全球分析Paediatric Neurology Device Market Forecasts to 2032 - Global Analysis By Product, Condition, Service & Treatment, End User and By Geography |
根据 Stratistics MRC 的数据,全球儿科神经设备市场预计在 2025 年达到 43 亿美元,到 2032 年将达到 79 亿美元,预测期内的复合年增长率为 8.9%。
儿科神经系统设备是专门用于诊断、监测和治疗从新生儿到青少年儿童神经病变的医疗设备或技术。这些医疗设备可治疗影响大脑、脊髓和周边神经系统的疾病,包括癫痫、脑性麻痹、发育迟缓和神经退化性疾病。其范围涵盖神经影像工具、脑电图系统、神经调节设备和穿戴式监测解决方案。这些专为儿科患者量身定制的设备优先考虑安全性、舒适性和准确性,从而能够及早发现、有效干预并改善儿童的长期神经系统健康状况。
根据美国癌症协会 (2023) 的统计,估计每年在儿童和青少年中诊断出超过 4,000 例脑和脊髓肿瘤。
儿童神经系统疾病盛行率上升
医院和诊所正在扩展其诊断和治疗能力,以应对复杂的儿科神经系统疾病。早发性疾病正在推动慢性器械的使用和多学科护理模式的发展。影像、监测和脑脊髓液管理方面的技术进步正在支持精准医疗。公共卫生措施和看护者意识的提升正在增强早期疗育。这些动态使疾病的流行成为儿科神经系统器械市场的关键驱动力,并推动整体市场的成长。
先进设备和程序高成本
规模较小的医院和资源匮乏的地区在实施和维护高端系统方面面临挑战。报销差距和有限的保险覆盖范围阻碍了新兴市场的普及。儿科客製化增加了设备开发的复杂性和成本。培训要求和法规遵从性进一步增加了营运成本。儘管临床需求不断增长,但这些因素仍在限制市场扩张。
更重视早期诊断和早期疗育
新生儿和儿科神经病学计画的扩展使得更早发现结构和功能异常成为可能。影像学、基因检测和数位监测的整合正在提高诊断的准确性。公共和私人部门对小儿科研究和医疗保健基础设施的投资正在推动技术创新。宣传宣传活动和学校筛检计画的范围正在扩大。这些发展为市场成长创造了有利条件,并加速了儿科神经病学设备的普及。
技术挑战和设备可靠性问题
设备故障、感染风险和再次手术引发了临床医生和看护者的担忧。製造商必须投资严格的测试、真实世界检验和上市后监测,以确保安全。全球市场的监管审查和责任风险正在加剧。儿科特定结果数据的有限性延缓了创新和核准进度。这些限制构成了策略风险,并限制了全面的市场推广。
新冠疫情扰乱了儿科神经病学设备市场,导致供应链暂时中断、生产停顿以及择期手术延迟。小儿科医院和神经病学中心的患者数量下降,影响了设备利用率和采购。然而,对远端神经病学、远端监控和数位诊断的关注度增加部分抵消了市场放缓的影响。疫情后的復苏将由对微创、技术驱动的儿科神经病学解决方案以及脑脊髓液管理和神经监测领域创新技术的需求成长所推动。
预测期内,脑脊髓液(CSF)管理设备市场预计将成为最大的市场
预计脑脊髓液 (CSF) 管理设备领域将在预测期内占据最大的市场份额,这得益于其在治疗水脑症和颅内高压方面的广泛应用。分流系统、引流套件和监测工具已部署在儿童神经外科病房。原始设备製造商 (OEM) 正在优化设备设计,考虑耐用性、感染控制和特定年龄层的适用性。医院、专科诊所和居家医疗的需求仍然强劲。监管部门对儿科设备技术创新的支持正在推动其应用。该领域继续在儿科神经系统设备市场占据主导地位,推动整体市场成长。
预计神经科科诊所部门在预测期内的复合年增长率最高
在预测期内,神经科诊所领域预计将实现最高成长率,这得益于对专科门诊儿科神经科护理的需求。诊所正在扩展神经诊断、发育评估和基于设备的干预等服务。与远端医疗、电子病历 (EMR) 系统和多学科团队的整合正在增强医疗服务。公共和私人对儿科神经科基础设施的投资正在加速诊所的扩张。对便利、以家庭为中心的医疗服务的需求正在增长。该领域正在成为儿科神经设备部署的高成长前沿,加速市场扩张。
在预测期内,北美预计将占据最大的市场份额,这得益于其先进的医疗基础设施、高度的疾病认知度以及强大的报销生态系统。美国和加拿大在儿科神经病学研究、设备创新和临床应用方面发挥主导作用。罕见疾病管理和神经发育护理领域的公共倡议正在增强需求。原始设备製造商和学术机构正在推动产品开发和监管核准。保险覆盖和临床试验活动正在支持其广泛应用。
在预测期内,亚太地区预计将呈现最高的复合年增长率,这得益于儿科人口的增长、医疗保健可及性的提高以及政府对儿科护理的投入。中国、印度、日本和韩国等国家正在扩大儿科神经病学计画和设备采购。官民合作关係和行动医疗计划正在改善医疗服务不足地区的诊断和治疗。对经济实惠的、特定年龄层设备的需求正在推动技术创新。区域製造商和全球公司正在合作,以在地化和扩展解决方案。
According to Stratistics MRC, the Global Pediatric Neurology Device Market is accounted for $4.3 billion in 2025 and is expected to reach $7.9 billion by 2032 growing at a CAGR of 8.9% during the forecast period. A Pediatric Neurology Device is a medical instrument or technology specifically designed to diagnose, monitor, or treat neurological disorders in children, from newborns to adolescents. These devices address conditions affecting the brain, spinal cord, and peripheral nervous system, including epilepsy, cerebral palsy, developmental delays, and neurodegenerative disorders. They range from neuroimaging tools and electroencephalography (EEG) systems to neuromodulation devices and wearable monitoring solutions. Tailored to pediatric patients, these devices prioritize safety, comfort, and accuracy, enabling early detection, effective intervention, and improved long-term neurological health outcomes in children.
According to the American Cancer Society (2023), it was estimated that more than 4,000 brain and spinal cord tumors were diagnosed each year in children and teens.
Rising prevalence of paediatric neurological disorders
Hospitals and clinics are expanding diagnostic and therapeutic capabilities to manage complex neurological conditions in children. Early-onset disorders are prompting long-term device use and multidisciplinary care models. Technological advancements in imaging, monitoring, and CSF management are supporting precision treatment. Public health initiatives and caregiver awareness are reinforcing early intervention. These dynamics are positioning disease prevalence as a key driver of the pediatric neurology device market, thereby boosting overall market growth.
High costs of advanced devices and procedures
Smaller hospitals and low-resource regions face challenges in acquiring and maintaining high-end systems. Reimbursement gaps and limited insurance coverage are slowing adoption in emerging markets. Customization for pediatric use adds complexity and cost to device development. Training requirements and regulatory compliance further increase operational overhead. These factors are tempering market expansion despite rising clinical demand.
Growing emphasis on early diagnosis and intervention
Expansion of neonatal and pediatric neurology programs is enabling earlier detection of structural and functional abnormalities. Integration with imaging, genetic testing, and digital monitoring is enhancing diagnostic accuracy. Public and private investments in pediatric research and care infrastructure are accelerating innovation. Awareness campaigns and school-based screening initiatives are expanding reach. These developments are creating favorable conditions for market growth, thereby accelerating adoption of pediatric neurology devices.
Technical challenges and device reliability issues
Device malfunction, infection risk, and revision surgeries are raising concerns among clinicians and caregivers. Manufacturers must invest in rigorous testing, real-world validation, and post-market surveillance to ensure safety. Regulatory scrutiny and liability risks are increasing across global markets. Limited data on pediatric-specific outcomes is slowing innovation and approval timelines. These limitations are introducing strategic risk and constraining full-scale market deployment.
The Covid-19 pandemic disrupted the Paediatric Neurology Device market, causing temporary supply chain interruptions, production halts, and delays in elective procedures. Paediatric hospitals and neurology centres experienced reduced patient volumes, impacting device utilization and procurement. However, the increased focus on tele-neurology, remote monitoring, and digital diagnostics partially offset the slowdown. Post-pandemic recovery is driven by growing demand for resilient, minimally invasive, and technology-enabled paediatric neurology solutions, along with innovations in CSF management and neuro-monitoring across care settings.
The cerebrospinal fluid (CSF) management devices segment is expected to be the largest during the forecast period
The cerebrospinal fluid (CSF) management devices segment is expected to account for the largest market share during the forecast period owing to its widespread use in treating hydrocephalus and intracranial pressure disorders. Shunt systems, drainage kits, and monitoring tools are being deployed across paediatric neurosurgical units. OEMs are optimizing device design for durability, infection control, and age-specific compatibility. Demand remains strong across hospitals, specialty clinics, and home care settings. Regulatory support for paediatric device innovation is reinforcing adoption. This segment continues to anchor the paediatric neurology device market, thereby boosting overall market growth.
The neurology clinics segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the neurology clinics segment is predicted to witness the highest growth rate driven by demand for specialized, outpatient-based paediatric neurological care. Clinics are expanding services in neurodiagnostics, developmental assessments, and device-based interventions. Integration with telehealth, EMR systems, and multidisciplinary teams is enhancing care delivery. Public and private investments in paediatric neurology infrastructure are accelerating clinic expansion. Demand for accessible, family-centered care is reinforcing momentum. This segment is emerging as a high-growth frontier for paediatric neurology device deployment, thereby accelerating market expansion.
During the forecast period, the North America region is expected to hold the largest market share due to its advanced healthcare infrastructure, high disease awareness, and strong reimbursement ecosystem. The U.S. and Canada are leading in paediatric neurology research, device innovation, and clinical adoption. Public initiatives in rare disease management and neurodevelopmental care are reinforcing demand. OEMs and academic institutions are driving product development and regulatory approvals. Insurance coverage and clinical trial activity are supporting widespread deployment.
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR driven by rising paediatric population, expanding healthcare access, and government investment in child health. Countries like China, India, Japan, and South Korea are scaling paediatric neurology programs and device procurement. Public-private partnerships and mobile health initiatives are improving diagnosis and treatment in underserved areas. Demand for affordable, age-specific devices is reinforcing innovation. Regional manufacturers and global players are collaborating to localize and scale solutions.
Key players in the market
Some of the key players in Paediatric Neurology Device Market include Medtronic plc, Boston Scientific Corporation, Philips Healthcare, Siemens Healthineers, GE Healthcare, Natus Medical Incorporated, Stryker Corporation, B. Braun Melsungen AG, Integra LifeSciences Corporation, Elana, Inc., Ethicon Inc., Inova Health System, The Nemours Foundation, BrainSpec Inc. and St. Jude Medical, Inc.
In June 2025, Philips launched IntelliSpace Cognition, a cloud-based platform for automated neuropsychological testing, now being adapted for pediatric use. The tool enables longitudinal tracking of cognitive development and supports early intervention in neurodevelopmental disorders.
In January 2025, Boston Scientific launched Cartesia(TM) directional leads and the Lumina 3D programming algorithm for DBS, now being adapted for paediatric use. These innovations improve precision and reduce side effects in children with epilepsy and dystonia.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.